Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Arcutis Biotherapeutics (ARQT) announced preliminary unaudited financial results for Q4 and full-year 2024. Q4 2024 product revenue is expected to reach approximately $63 million, showing a 366% increase compared to Q4 2023 and 41% growth from Q3 2024. Full-year 2024 product revenue is anticipated at approximately $160 million, up 449% from 2023.

The company's growth was driven by strong demand across all ZORYVE® (roflumilast) indications, maintaining similar gross-to-net (GTN) levels as the previous quarter. As of December 31, 2024, preliminary cash, cash equivalents, restricted cash, and marketable securities stood at approximately $229 million. The company previously repaid $100 million of long-term debt to SLR Investment Corp., with an option to re-draw approximately $100 million by first half 2026, bringing total liquidity to approximately $329 million.

Arcutis Biotherapeutics (Nasdaq: ARQT) has announced the grant of 75,500 restricted stock units to eight newly hired employees. The awards were approved by the company's Compensation Committee and granted under the Arcutis Biotherapeutics 2022 Inducement Plan on January 2, 2025. The stock units are structured with a four-year vesting schedule, with 25% vesting annually on each anniversary of the vesting commencement date. The grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4), and continued employment is required for vesting.

Arcutis Biotherapeutics (ARQT) has submitted a supplemental New Drug Application (sNDA) to the FDA for ZORYVE® (roflumilast) cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2-5 years. The submission is supported by positive Phase 3 trial results involving 652 children, where 25.4% of treated patients achieved vIGA-AD Success compared to 10.7% with vehicle at Week 4.

The cream demonstrated rapid itch reduction, with 35.3% of treated children achieving a four-point reduction in Worst Itch Numeric Scale at Week 4 versus 18.0% for vehicle. The treatment showed a favorable safety profile over 56 weeks, with common side effects including upper respiratory infection, diarrhea, and vomiting. The potential market includes approximately 1.8 million children with atopic dermatitis aged 2-5 who are topically treated in the US.

Arcutis Biotherapeutics (ARQT) has granted a total of 44,000 restricted stock units (RSUs) to six newly hired employees. The grants were approved by the company's Compensation Committee and issued under the 2022 Inducement Plan on December 2, 2024. The RSUs will vest over a four-year period, with 25% vesting annually, contingent on continuous employment. This action complies with Nasdaq Listing Rule 5635(c)(4), which governs inducement grants for new employees.

Arcutis Biotherapeutics (ARQT) announced key executive promotions to support company growth and strengthen the ZORYVE® portfolio. Patrick Burnett was promoted to Executive VP, Chief Medical Officer, recognized for leading pipeline advancement and securing multiple regulatory approvals. L. Todd Edwards was elevated to Executive VP, Chief Commercial Officer, credited with revamping commercial operations and driving ZORYVE franchise growth. Kent Taylor was promoted to Senior VP of Sales, acknowledged for strong performance in launching ZORYVE foam and cream products.

Arcutis Biotherapeutics' ZORYVE® (roflumilast) cream 0.15% has received Glamour's 2024 Health and Wellness award for Best Eczema Product in the Best Beauty Innovators category. ZORYVE is the first FDA-approved once-daily topical treatment for mild to moderate atopic dermatitis in patients aged 6 and older. The treatment, approved in July 2024, is a next-generation topical PDE4 inhibitor that can be applied anywhere on the body for any duration. Atopic dermatitis, the most common type of eczema, affects approximately 9.6 million children and 16.5 million adults in the United States.

Arcutis Biotherapeutics (ARQT) reported strong Q3 2024 financial results with total product revenues of $44.8 million, representing 452% growth year-over-year and 45% quarter-over-quarter. The revenue breakdown includes $22.0M from ZORYVE cream 0.3%, $20.3M from ZORYVE foam 0.3%, and $2.5M from ZORYVE cream 0.15%. The company improved its gross-to-net ratio to low 50% range and saw a 25% increase in total franchise unit demand. The FDA accepted their sNDA for ZORYVE foam for scalp and body psoriasis with a PDUFA date of May 22, 2025. Health Canada approved ZORYVE foam for seborrheic dermatitis with launch planned by end of 2024.

Arcutis Biotherapeutics (Nasdaq: ARQT) announced the grant of equity incentives to five new employees. The compensation package includes 50,000 restricted stock units and options to purchase 50,000 shares of common stock at $8.67 per share. The restricted stock units vest over four years with 25% annual vesting, while stock options vest 25% after one year and the remainder monthly over three years. The grants were approved under the company's 2022 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).

Arcutis Biotherapeutics (ARQT) presented new patient-reported outcome data for ZORYVE® cream 0.15% in treating atopic dermatitis at ACAAI 2024. The Phase 3 INTEGUMENT-1 and -2 trials showed significant improvements across multiple metrics: 64.2% of ZORYVE-treated patients achieved meaningful improvement in SCORAD Total Score vs 36.3% for vehicle at Week 1, and 61.7% showed improvement in POEM scores vs 34.2% for vehicle. The treatment met its primary efficacy endpoint with 31.3% achieving Investigator Global Assessment Success vs 14.1% for vehicle, demonstrating rapid improvement in disease clearance, itch reduction, and quality of life measures for patients and caregivers.